Rituxan is a prescription drug approved by the Food and Drug Administration (FDA) to treat non-Hodgkin lymphoma (NHL). Rituxan may be prescribed as alone or in combination with other anti-lymphoma drugs. Rituxan may be used as part of a chemotherapy regimen or as maintenance therapy after a course of chemotherapy has been completed. Rituxan is also known by its drug name, Rituximab.
Rituxan is used in immunotherapy for cancer. Rituxan is a biologic drug – a genetically engineered protein, or antibody – that attacks specific targets. In cases of NHL, Rituxan is believed to work by attacking the CD20 antigen, a protein located on the surface of white blood cells called B-lymphocytes. read more
How do I take it?
Rituxan is administered as an intravenous infusion. The frequency of Rituxan administration depends on how the drug is being used, but prescribing information lists once-weekly administration for most usages in cases of NHL.
Rituxan comes in the form of a single-dose vial.
The FDA-approved label for Rituxan lists common side effects including fever, chills, weakness, increased risk for infections, and infusion reactions.
Rare but serious side effects listed for Rituxan can include life-threatening cardiac events, kidney dysfunction, bowel obstruction or perforation, fetal harm in pregnant women, and tumor lysis syndrome (a potentially fatal metabolic condition caused when many cancer cells die at the same time).
For more details about this treatment, visit:
Rituxan – Genentech
Immunotherapy for Non-Hodgkin Lymphoma – American Cancer Society
Immunotherapy – Lymphoma Research Foundation